Generate Biomedicines priced a $400 million IPO to fund pivotal trials of its TSLP‑targeting program and expanded R&D into AI‑driven protein therapeutics. The Flagship Pioneering‑backed company will list under the ticker GENB and said proceeds will underwrite phase‑critical testing of its lead candidate GB‑0895 for severe asthma along with platform advancement efforts. The offering highlights sustained investor appetite for AI‑first biotech platforms despite broader market volatility. Generate positioned the raise as a financing bridge to larger late‑stage milestones and emphasized plans to use computational design to create proteins with improved dosing and stability profiles.